Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients

Who May Be Eligible (Plain English)

Who May Qualify: Inclusion Criteria for Sickle Cell Patients 1. Adults: \> 15 years and 6 months 2. Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 3. Known SS or Sβ0 phenotypes Inclusion Criteria for Control Patients. 1 -Adults: \> 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration -Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder 4-Blood sample planned as part of medical care Who Should NOT Join This Trial: 1. Hemoglobin disorder other than sickle cell disease (Criteria for Sickle Cell Patients) 2. Hemoglobinopathies other than sickle cell disease (Criteria for Control Patients) 3. Transfusion less than 3 months ago 4. Chronic active viral disease: hepatitis B, C, HIV 5. Current infections or known inflammatory pathologies 6. Known hyper or hypothyroidism or subject treated with levothyroxine 7. Active tumor pathology or remission for less than 5 years 8. Oral corticosteroid therapy in progress 9. Participation in interventional biomedical research 10. Opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor. 11. Non-affiliation to a social security system Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: Inclusion Criteria for Sickle Cell Patients 1. Adults: \> 15 years and 6 months 2. Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 3. Known SS or Sβ0 phenotypes Inclusion Criteria for Control Patients. 1 -Adults: \> 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration -Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder 4-Blood sample planned as part of medical care Exclusion Criteria: 1. Hemoglobin disorder other than sickle cell disease (Criteria for Sickle Cell Patients) 2. Hemoglobinopathies other than sickle cell disease (Criteria for Control Patients) 3. Transfusion less than 3 months ago 4. Chronic active viral disease: hepatitis B, C, HIV 5. Current infections or known inflammatory pathologies 6. Known hyper or hypothyroidism or subject treated with levothyroxine 7. Active tumor pathology or remission for less than 5 years 8. Oral corticosteroid therapy in progress 9. Participation in interventional biomedical research 10. Opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor. 11. Non-affiliation to a social security system

Treatments Being Tested

BIOLOGICAL

Measurement of AHSP concentration

Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC. The 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory.

Locations (1)

Centre Hospitalier de Saint-Denis
Saint-Denis, France